Quantumzyme to Participate in BioLogic Summit 2026, Emphasizing AI-Driven Innovation in Biopharmaceutical Manufacturing

Quantumzyme Corp., a biotransformation company focused on sustainable pharmaceutical manufacturing, announced its team will attend the second annual BioLogic Summit scheduled for January 19-22, 2026, in San Diego. The summit represents a premier event concentrating on machine learning and artificial intelligence applications for biotherapeutics design and optimization. This participation underscores Quantumzyme's strategic commitment to remaining engaged in rapidly evolving fields of AI-enabled enzyme engineering and protein design.

The conference provides an opportunity for the company's scientific leadership to participate in technical discussions, share insights with peers, and explore emerging advancements aligning with internal development efforts. These activities support the company's proposed strategic evolution to Quantum Genesis AI Corp., pending FINRA approval. The BioLogic Summit specifically caters to hybrid scientists integrating experimental and computational methods, reflecting the expertise of the Quantumzyme team. Attendance aims to keep the company informed about latest developments in generative AI, lab-in-the-loop optimization, and structure-based design approaches.

These insights support continued advancement of the company's platform and help ensure alignment with relevant methodologies in the field. Naveen Kulkarni, CEO of Quantumzyme Corp., stated that innovation doesn't happen in isolation, emphasizing that active engagement with brightest minds in the field remains essential to driving the company's mission forward. The BioLogic Summit provides a valuable venue for the team to connect with individuals and organizations contributing to AI's future in biologics. The goal involves learning from latest research, better understanding emerging challenges, and exploring potential collaborations supporting adoption of greener, more efficient manufacturing approaches across the pharmaceutical industry.

For more information and updates, please visit https://www.quantumzymecorp.com and the company's profile at https://www.otcmarkets.com/stock/QTZM. The information contained in this press release is provided by Quantumzyme Corp. for general informational purposes only. This release may include forward-looking statements reflecting current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements.